Product News from the May 20 MM&M News Brief

Share this article:

Product News
The FDA granted traditional approval status to GlaxoSmithKline's Trizivir (abacavir sulfate, lamivudine and zidovudine) for the treatment of HIV infection. Trizivir is the first and only FDA-approved, fixed-dose-combination drug for HIV that combines three drugs into one tablet, GSK said.

Roche has decided to discontinue the sale and distribution of its HIV medication Fortovase (saquinavir), as clinical demand for the drug has declined significantly due to the availability of a new formulation of Invirase (saquinavir mesylate). The removal of Fortovase, which will be discontinued during the first quarter of 2006, is completely voluntary and is not due to safety or efficacy issues, Roche said.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.